Group One Trading, L.P. Beyond Spring Inc. Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.67 - $1.12 $3,628 - $6,065	-5,416 Reduced 8.68%	56,986 $51,000
Q3 2023 Nov 09, 2023	SELL	$0.75 - $1.16 $446 - $690	-595 Reduced 0.94%	62,402 $49,000
Q2 2023 Aug 09, 2023	SELL	$0.89 - $1.39 $1,393 - $2,176	-1,566 Reduced 2.43%	62,997 $74,000
Q1 2023 May 12, 2023	BUY	$1.06 - $3.05 $3,695 - $10,632	3,486 Added 5.71%	64,563 $72,000
Q4 2022 Feb 09, 2023	BUY	$0.56 - $2.61 $8,416 - $39,225	15,029 Added 32.64%	61,077 $114,000
Q3 2022 Nov 09, 2022	SELL	$0.97 - $1.81 $16,724 - $31,208	-17,242 Reduced 27.24%	46,048 $46,000
Q2 2022 Aug 11, 2022	BUY	$1.13 - $2.66 $1,053 - $2,479	932 Added 1.49%	63,290 $91,000
Q1 2022 May 12, 2022	SELL	$1.68 - $5.01 $75,919 - $226,401	-45,190 Reduced 42.02%	62,358 $137,000
Q4 2021 Feb 11, 2022	BUY	$4.02 - $16.84 $219,781 - $920,676	54,672 Added 103.4%	107,548 $487,000
Q3 2021 Nov 12, 2021	BUY	$9.26 - $31.31 $489,631 - $1.66 Million	52,876 New	52,876 $833,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.